PHAXIAM Therapeutics Email Format
Biotechnology ResearchAuvergne-Rhône-Alpes, France11-50 Employees
PHAXIAM Therapeutics is a biopharmaceutical company focused on developing treatments for resistant bacterial infections, using bacteriophages to target bacteria. The company is building a portfolio aimed at three high-priority pathogens—Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa—that together account for a majority of resistant hospital‑acquired infections. Based in Lyon in the Auvergne-Rhône-Alpes region of France, it operates as a small biotechnology firm. PHAXIAM is publicly traded on the Nasdaq Capital Market and on Euronext in Paris, and it is included in several market indices. In November 2024, PHAXIAM partnered with Phage Canada to organize Phagogram Day, a collaborative event focusing on developing phagograms and in‑vitro testing to assess phage susceptibility of clinical strains.
1-888-653-2347 
support@leadiq.com 
